mRNA compositions for the treatment or improvement of acute myocardial infarction, as well as engineered cells and grafts.

By optimizing and transfecting IL4, IL10, VEGFA, and bFGF mRNA into cardiomyocytes to form engineered cells, the problems of microenvironment regulation and mRNA stability after myocardial infarction were solved, achieving multiple improvements and recovery of cardiac function.

CN123101705APending Publication Date: 2026-11-17SHANGHAI CHILDRENS MEDICAL CENT AFFILIATED TO SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611611005.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, the dynamic pathophysiological processes of the microenvironment after myocardial infarction are difficult to fully regulate, and the stability and translation efficiency of mRNA are not ideal, which limits the improvement of the efficacy of hiPSC-CMs therapy, results in low graft survival rate, and makes it difficult to achieve effective recovery of cardiac function.

Method used

The mRNAs of IL4, IL10, VEGFA, and bFGF were optimized, and the optimized mRNAs were transfected into human induced pluripotent stem cell-derived cardiomyocytes to form engineered cells, which were used as grafts for cardiac function recovery. By co-expressing VEGFA, bFGF, IL-4, and IL-10 proteins, multiple functions were achieved to promote myocardial repair.

Benefits of technology

Engineered cells rapidly, efficiently, and continuously co-express optimized proteins in the heart, significantly improving cardiac function, preventing ventricular wall thinning and ventricular dilation, reducing cardiomyocyte death, promoting angiogenesis, inhibiting myocardial fibrosis, delaying damage progression, and achieving myocardial function recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101705A_ABST
    Figure CN123101705A_ABST
Patent Text Reader

Abstract

The purpose of this invention is to achieve effective recovery of cardiac function after acute myocardial infarction through hiPSC-CMs therapy. Specifically, it provides an mRNA composition for treating or improving acute myocardial infarction, comprising: optimized IL4 mRNA, sequence as shown in SEQ ID No. 1; optimized IL10 mRNA, sequence as shown in SEQ ID No. 2; optimized VEGFA mRNA, sequence as shown in SEQ ID No. 3; and optimized bFGF mRNA, sequence as shown in SEQ ID No. 4. This invention also provides engineered cells transfected with this mRNA composition and grafts containing this engineered cell composition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology and relates to an mRNA composition for treating or improving acute myocardial infarction, as well as cells and grafts containing the mRNA composition. Background Technology

[0002] Myocardial infarction (MI) remains one of the leading causes of high morbidity and mortality worldwide. Due to the irreversible loss of cardiomyocytes, patients often progress to heart failure, and conventional therapies are often insufficient to restore lost myocardial function due to the limited regenerative capacity of adult heart tissue.

[0003] To restore myocardial function, existing technologies include regenerative therapies based on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), such as cell application alone, combined application with adipose-derived stem cells, or construction of cardiac spheroids and self-organized 3D organoids. These cell therapies can not only provide structural support by directly replacing cardiomyocytes but also promote repair by modulating the infarct microenvironment through paracrine signaling. However, low graft survival rates and the harsh post-infarction microenvironment remain major bottlenecks hindering their clinical translation.

[0004] In recent years, mRNA technology has made groundbreaking progress, especially with the establishment of nucleoside modification technology, which has enabled transient and efficient protein expression. Preclinical studies have shown that intramyocardial injection of mRNA (especially delivery of pro-angiogenic factors) has significant potential as a treatment strategy for myocardial infarction (MI). However, many challenges remain in translating this technology into clinical applications, including the easy degradation of mRNA, limited transfection efficiency, and difficulty in mimicking the endogenous myocardial regeneration process.

[0005] Previous research by the inventors of this application has demonstrated that combining hiPSC-CMs with mRNA delivery targeting vascular endothelial growth factor A (VEGFA) significantly enhances graft survival and improves overall efficacy compared to monotherapy. However, the clinical potential of this strategy is still limited by two major factors: firstly, the post-infarction microenvironment involves multiple dynamic pathophysiological processes, making comprehensive regulation difficult with single-target intervention; secondly, the stability and translation efficiency of mRNA remain insufficient, limiting its protein expression level and hindering further improvement in efficacy. Summary of the Invention

[0006] This invention was developed to address the aforementioned problems, aiming to achieve comprehensive regulation of the post-infarction microenvironment and enhance the protein expression level of mRNA, thereby improving the therapeutic effect of hiPSC-CMs therapy and ultimately achieving effective recovery of cardiac function after acute myocardial infarction through hiPSC-CMs therapy.

[0007] This invention optimizes the mRNA sequences of IL4, IL10, VEGFA, and bFGF, and uses the optimized IL4, IL10, VEGFA, and bFGF mRNAs to enhance the function of cardiomyocytes (iPSC-CMs) differentiated from human induced pluripotent stem cells (hiPSCs). The enhanced iPSC-CMs can co-deliver and co-express the optimized VEGFA, bFGF, IL-4, and IL-10 proteins, and when used as grafts or part of grafts, they can significantly improve and restore cardiac function, demonstrating good application potential.

[0008] Specifically, the present invention provides an mRNA composition for treating or improving acute myocardial infarction, comprising: optimized IL4 mRNA, the sequence of which is shown in SEQ ID No. 1; optimized IL10 mRNA, the sequence of which is shown in SEQ ID No. 2; optimized VEGFA mRNA, the sequence of which is shown in SEQ ID No. 3; and optimized bFGF mRNA, the sequence of which is shown in SEQ ID No. 4.

[0009] The present invention also provides engineered cells for the treatment or improvement of acute myocardial infarction, characterized in that they are obtained by transfecting cardiomyocytes with the above-described mRNA composition.

[0010] Preferably, the cardiomyocytes are cardiomyocytes derived from human induced pluripotent stem cells.

[0011] The present invention further provides a graft for treating or improving acute myocardial infarction, which contains engineered cells as described above.

[0012] Preferably, the graft provided by the present invention for treating or improving acute myocardial infarction further comprises adipose-derived stem cells.

[0013] In addition, preferably, the graft provided by the present invention for treating or improving acute myocardial infarction can be a cardiac spheroid or a self-organized 3D organoid.

[0014] According to the mRNA composition and engineered cells provided by the present invention, since the composition contains four optimized mRNAs, after transfection into human induced pluripotent stem cell-derived cardiomyocytes and other cardiomyocytes, the obtained engineered cells can rapidly, efficiently, and continuously co-express optimized VEGFA, bFGF, IL-4, and IL-10 proteins. This enables the engineered cells to play multiple roles after transplantation to the heart, including preventing ventricular wall thinning and ventricular dilation, reducing cardiomyocyte death, synergistically promoting angiogenesis, effectively inhibiting myocardial fibrosis, improving ventricular pathological remodeling, and delaying the progression of myocardial injury, thereby effectively promoting myocardial repair and realizing the recovery of myocardial function after acute myocardial infarction. Attached Figure Description

[0015] Figure 1 This is a flowchart of sequence optimization according to Embodiment 1 of the present invention.

[0016] Figure 2 This is a scatter plot of the four types of mRNA iterative mutagenesis and screening in Example 1 of the present invention.

[0017] Figure 3 This is a graph showing the changing trends of MFE and CAI during mRNA mutagenesis.

[0018] Figure 4 This is a structural comparison diagram of the original coding sequences (CDS) of four mRNAs and their optimized coding sequences.

[0019] Figure 5 This is a graph showing the quantitative analysis results of secreted protein levels at different time points in H9C2 cells transfected with mRNA before or after optimization in Example 1 of the present invention (n = 3).

[0020] Figure 6 This is a representative immunofluorescence image of how the expressed protein of Op-IL4 after transfection into H9C2 cells promotes RAW polarization to M2 in Example 1 of this invention.

[0021] Figure 7 This is a graph showing the relative mRNA expression levels of CD206, Arg-1, and TGF-β1, markers of M2 macrophages transfected with IL4 or Op-IL4 in Example 1 of this invention (n = 3).

[0022] Figure 8 This is a graph showing the detection results of pro-inflammatory cytokine release in an inflammatory injury model after Op-IL-10 transfection of H9C2 cells in Example 1 of this invention.

[0023] Figure 9 This is a graph showing the ELISA quantitative measurement results of the levels of cytokines (IL-1β, TNF-α and IL-6) in H9C2 cells transfected with IL-10 or Op-IL-10 in Example 1 of this invention (n = 3).

[0024] Figure 10 The images show the effects of the VEGFA and Op-VEGFA proteins expressed in H9C2 cells after transfection with VEGFA in Example 1 of this invention on angiogenesis in HUVECs.

[0025] Figure 11 The images show the results of HUVECs cell migration after the expression proteins of VEGFA and Op-VEGFA transfected into H9C2 cells in Example 1 of this invention.

[0026] Figure 12The figure shows the results of the analysis of the effects of the VEGFA and Op-VEGFA expressed proteins after transfection of H9C2 cells in Example 1 of this invention on the formation (branching and number of tubes) and wound healing ability of HUVECs (n = 3).

[0027] Figure 13 This is a flow cytometry analysis result of apoptotic cell populations after transfection with bFGF or Op-bFGF mRNA according to Example 1 of the present invention. Figure 14 Is with Figure 13 The corresponding analysis results are shown in a bar chart.

[0028] Figure 15 This is a graph showing the ELISA quantitative analysis results of four factors in rat heart tissue at different time points after hiPSC-CMs transplantation in Example 1 of this invention (n = 4).

[0029] Figure 16 This is an electrocardiogram monitoring result of the rat MI model constructed in Example 2 of the present invention at 5 minutes.

[0030] Figure 17 This is a graph showing the measurement results of left ventricular injury 24 hours after the rat MI model constructed in Example 2 of this invention.

[0031] Figure 18 This is a cardiac echocardiogram of a rat three days after myocardial infarction, according to Example 2 of the present invention.

[0032] Figure 19 These are representative echocardiograms of rats in each group at 1, 2, and 4 weeks after myocardial infarction in Example 2 of this invention.

[0033] Figure 20 This is a graph showing the quantitative assessment results of left ventricular function in each group of rats at 1, 2 and 4 weeks after myocardial infarction in Example 2 of the present invention.

[0034] Figure 21 This is a representative 64-channel left ventricular activation map (thermograph) of each group of rats 4 weeks after myocardial infarction in Example 2 of the present invention.

[0035] Figure 22 This is a graph showing the quantitative analysis results of ventricular conduction parameters (time, velocity, and heterogeneity) of each group of rats 1 week and 4 weeks after myocardial infarction in Example 2 of the present invention (n = 8).

[0036] Figure 23 These are representative H&E-stained heart tissue slices from each group of rats 4 weeks after myocardial infarction in Example 2 of this invention.

[0037] Figure 24This is a graph showing the quantitative analysis results of the left ventricular infarction area of ​​H&E sections of rats in each group 1 week and 4 weeks after myocardial infarction in Example 2 of the present invention (n = 8).

[0038] Figure 25 This refers to MI-CMs 4 weeks post-transplantation in Example 3 of the present invention. Cocktail Image showing the detection results of viable myocardial grafts in the ischemic zone (IZ) and marginal zone (BZ).

[0039] Figure 26 , Figure 27 These are representative immunofluorescence images of the infarct margin region at 1 week and 4 weeks after myocardial infarction in Example 3 of the present invention, showing co-localization of graft-derived cardiomyocytes (cTnT, red) and GFP-labeled transplanted cells (green).

[0040] Figure 28 This is a graph showing the quantitative analysis results of relative GFP fluorescence intensity in cardiac tissue at 1 week and 4 weeks after myocardial infarction in Example 3 of the present invention (n = 8).

[0041] Figure 29 These are confocal microscopy images of TUNEL (red) and cTnT (green) positive cardiomyocytes in the marginal zone (BZ) at 1 week and 4 weeks after myocardial infarction, according to Example 3 of the present invention.

[0042] Figure 30 This is a graph showing the quantitative analysis results of TUNEL-positive cardiomyocytes per field of view in six groups of the present invention at 1 week and 4 weeks after myocardial infarction.

[0043] Figure 31 These are confocal micrographs of CD31 and α-SMA staining after Example 4 of this invention. Figure 32 yes Figure 31 The corresponding quantitative analysis results are shown in the figure.

[0044] Figure 33 This is a Masson trichrome staining image of rat heart tissue after myocardial infarction, as described in Example 4 of this invention.

[0045] Figures 34-36 The results are the staining detection results of the inflammatory markers CD3, CD68, and MIPO one week after the operation of Example 4 of the present invention. Figures 34-36 In the diagram, 'a' represents the stained images of the corresponding inflammatory markers, and 'b' represents the bar charts of the results corresponding to 'a'.

[0046] Figure 37 These are representative immunofluorescence images of collagen I and III co-stained with cTnT in Example 4 of this invention.

[0047] Figure 38 This is a graph showing the quantitative analysis results of the content of type I and type III collagen in each group of heart tissue in Example 4 of the present invention (n = 8).

[0048] Figure 39 This is the result of vimentin staining in cardiomyocytes 4 weeks after myocardial infarction, according to Example 4 of the present invention. Figure 39 In the diagram, 'a' represents the stained image, and 'b' is the corresponding histogram of the result.

[0049] Figure 40 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Representative electrocardiogram trajectories in lead II recorded at different time points in the group.

[0050] Figure 41 These are representative lead II electrocardiogram trajectories recorded at different time points in the MI group of Embodiment 5 of the present invention.

[0051] Figure 42 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Echocardiography of left ventricular function at specific time points after myocardial infarction in the PBS group and the PBS group.

[0052] Figure 43 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Statistical analysis results of key left ventricular function parameters in the PBS group and the PBS group.

[0053] Figure 44 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Representative short-axis MRI images of the heart morphology (basal segment, mid-ventricular segment, and apical segment, with the infarct area marked in color) of the group and the PBS group before myocardial infarction surgery, 3 days after surgery, and 28 days after surgery. Figure 45 Is with Figure 44 The corresponding quantitative analysis results of functional parameters based on MRI assessment are shown in the figure.

[0054] Figure 46 This is a polar coordinate diagram (bull's eye diagram) representing the regional myocardial function at three ventricular levels at different time points in Embodiment 5 of the present invention. Figure 47 Is with Figure 46 The corresponding quantitative analysis results of the functional parameters based on the bullseye chart assessment are shown in the figure.

[0055] Figure 48 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Coronary angiography images acquired 28 days after myocardial infarction in the control group and the PBS group.

[0056] Figure 49 This is the MI-CMs of Embodiment 6 of the present invention.Cocktail Images of heart specimens collected on day 28 in the control group and the PBS group.

[0057] Figure 50 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Representative H&E and Masson stained tissue sections from the MI-PBS group 4 weeks after myocardial infarction.

[0058] Figure 51 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the results of quantitative analysis of infarct area and left ventricular wall thickness 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0059] Figure 52 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence co-staining images of CD31⁺ capillaries (red) and α-SMA⁺ adventitia cells (green) in the infarct zone (IZ) and boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the infarct group (magnified area scale bar, 50 µm).

[0060] Figure 53 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Image showing the vascular morphology analysis results of the group and the MI-PBS group.

[0061] Figure 54 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Representative TUNEL staining (green) and DAPI counterstaining images (scale bar, 50 µm) of apoptotic cells in the boundary zone (BZ) of myocardial infarction 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0062] Figure 55 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the quantitative analysis results of TUNEL-positive cell nuclei in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0063] Figure 56 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence staining and DAPI counterstaining images of vimentin (green) in the boundary zone (BZ) of myocardial infarction in the MI-PBS group and the MI-PBS group 4 weeks after myocardial infarction (scale bar, 50 µm).

[0064] Figure 57 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the quantitative analysis results of vimentin-positive cells in the heart tissue of the MI-PBS group and the MI-PBS group.

[0065] Figure 58 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence colocalization images of cTnT (green) and type I collagen (red) in the boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group (scale bar, 50 µm).

[0066] Figure 59 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Quantitative analysis results of type I collagen-positive areas in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0067] Figure 60 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence colocalization images of cTnT (green) and type III collagen (red) in the boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group (scale bar, 50 µm).

[0068] Figure 61 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Quantitative analysis results of type III collagen-positive areas in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0069] Figure 62 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure 1. Quantitative PCR analysis results of Y chromosome DNA in the infarct zone (IZ) 4 weeks after myocardial infarction in the MI-PBS group and the infarct group.

[0070] Figure 63 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Results of multiple blood biochemical indicators at various time points after myocardial infarction in the MI-PBS group and the MI-PBS group. Figure 63 In the diagram, a represents troponin, b represents white blood cell count (WBC), c represents basophils (BAS), d represents red blood cells (RBC), and e represents alanine aminotransferase (ALT). Detailed Implementation

[0071] This invention optimizes IL4, IL10, VEGFA, and bFGF mRNA, and uses the optimized IL4, IL10, VEGFA, and bFGF mRNA to functionally modify human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to obtain engineered cells. These engineered cells were further introduced into rat and pig MI models through enhanced cell colonization. The results showed that these engineered cells can promote angiogenesis, inhibit inflammatory responses, and reduce fibrosis, ultimately restoring cardiac function in both rats and pigs. This indicates that the engineered cell therapy based on the optimized IL4, IL10, VEGFA, and bFGF mRNA composition of this invention (hereinafter referred to as Cocktail therapy) can be used clinically for MI treatment and cardiac function improvement.

[0072] To make the technical means, creative features, achieved objectives and effects of this invention easily understood, the following embodiments, in conjunction with the accompanying drawings, illustrate specific implementation methods of this invention. In the following embodiments and test examples, reagents and materials not specified were all purchased through general commercial channels, and experimental operations and conditions not described were performed in accordance with conventional operations and conditions in the art.

[0073] In addition, all data in the following embodiments are expressed as mean ± standard deviation. For parametric tests of two independent samples, unpaired two-tailed Student's t-test was used. When comparing more than two independent groups, one-way ANOVA was used, followed by appropriate post-hoc tests according to predefined rules: Tukey's test for homogeneity of variance and Bonferroni correction for specific paired comparisons. All statistical analyses were performed using GraphPad Prism software (version 9.5), and outliers were assessed using the Grubbs test where applicable. Statistical significance was defined as p < 0.05.

[0074] Example 1

[0075] This embodiment provides the optimized IL4, IL10, VEGFA, and bFGF mRNA sequences and their optimization process.

[0076] This invention innovatively develops the V2 mutation algorithm, which can simultaneously screen for optimal sequences based on codon fitness index (CAI) and minimum free energy (MFE). Preliminary experiments show that starting with natural sequences with low codon fitness index (CAI) hinders the rapid generation of high-performance variants. Therefore, this invention uses a fully codon-optimized sequence as the starting template, that is, completely replacing the natural coding sequence of the target gene with codons preferred by the host expression system, so that the codon fitness index reaches the optimal level (CAI = 1).

[0077] The minimum free energy (MFE) is calculated on a computer using the LinearFold algorithm based on the CONTRAfold energy model, and the codon fitness index (CAI) is quantified using an internal computational process. This invention establishes a composite scoring model to balance structural stability and translation efficiency, defined as follows: Score = a × MFE_score + b × CAI, where the weighting coefficients a and b are experimentally adjusted to reflect the relative importance of RNA secondary structure stability and translation efficiency. After each round of mutation, a two-dimensional scatter plot of "score-CAI" is generated using MATLAB to select the best-performing sequence for the next iteration. The optimization process is repeated until the score converges or a predetermined number of rounds is reached, thereby ensuring a gradual and refined improvement in variant performance.

[0078] Figure 1 This is a flowchart of sequence optimization according to Embodiment 1 of the present invention.

[0079] like Figure 1 As shown, the specific implementation process of sequence optimization of the present invention includes:

[0080] Step S1: Replace the codons in the target protein CDS sequence with the most frequently used codons to generate a sequence with CAI=1;

[0081] Step S2 involves performing random mutations by replacing synonymous codons and monitoring changes in MEF and CAI of the mutated sequence;

[0082] Step S3: Select sequences with excellent MFE and CAI performance from each round of mutation as the initial sequences for the next round of mutation cycle;

[0083] Step S4: Calculate a × MFE_score + b × CAI and determine if it is greater than the threshold. If it is not greater than the threshold or the maximum number of iterations has not been reached, return to step S2. If it is greater than the threshold or the maximum number of iterations has been reached, end the process and select the best sequence from the results.

[0084] In this embodiment, the mRNA sequences of IL-4, IL-10, VEGFA, and bFGF before optimization were all human mRNAs, obtained from NCBI.

[0085] Figure 2 This is a scatter plot of the four types of mRNA iterative mutagenesis and screening in Example 1 of this invention. Figure 3 This is a diagram showing the changes in MFE and CAI during mRNA mutagenesis. Figure 4 This is a structural comparison diagram of the original coding sequences (CDS) of four mRNAs and their optimized coding sequences.

[0086] like Figures 2-4 As shown, after multiple rounds of mutant screening, the structures of the four optimized mRNAs obtained were significantly different from the initial structures. The sequences of the four optimized mRNAs are as follows:

[0087] The optimized IL4 (denoted as Op-IL-4) sequence is shown in SEQ ID No. 1;

[0088] The optimized IL10 (denoted as Op-IL10) sequence is shown in SEQ ID No. 2;

[0089] The optimized VEGFA (denoted as Op-VEGFA) sequence is shown in SEQ ID No. 3;

[0090] The optimized bFGF (denoted as Op-bFGF) sequence is shown in SEQ ID No. 4.

[0091] To compare the target protein expression levels of the four optimized mRNAs with those before optimization, this embodiment prepared mRNA samples before and after optimization, respectively, and transfected them into H9C2 cells. The target protein expression levels in the transfected H9C2 cells were then detected. The specific transfection procedures are as follows:

[0092] Modified mRNA (modRNA) was synthesized using a T7 RNA polymerase-driven in vitro transcription system, in which N1-methylpseudouridine (1-mψ) replaced uridine. The RNA was then purified using standard column purification protocols. For transfection, the synthesized modRNA was delivered to target cells using RNAiMAX transfection reagents according to the manufacturer's recommended protocol.

[0093] Figure 5 This is a graph showing the quantitative analysis results of secreted protein levels at different time points in H9C2 cells transfected with mRNA before or after optimization in Example 1 of the present invention (n = 3).

[0094] like Figure 5As shown, all mRNAs rapidly initiated protein secretion within 48 hours post-transfection, and the secretory activity persisted for over 96 hours. Enzyme-linked immunosorbent assay (ELISA) quantitative analysis revealed that, compared to the unoptimized control group, the expression levels of Op-IL4 and Op-IL10 were significantly increased at all time points; Op-VEGFA expression increased slightly, but not statistically significantly; Op-bFGF exhibited a unique bimodal expression pattern, with peaks occurring at 24 hours and 72–96 hours, respectively, and the expression levels at both time points showed statistically significant differences. Therefore, the mRNAs in this invention can efficiently transfect H9C2 cells, achieving rapid initiation and sustained expression of secreted proteins. Furthermore, compared to the four mRNAs before optimization, the four optimized mRNAs significantly improved the expression levels of the target proteins.

[0095] This embodiment further validates the functional specificity of the four optimized mRNA-expressed proteins in vitro at the cellular level using the H9C2 cells obtained by the above transfection.

[0096] 1. Functional specificity of proteins expressed in H9C2 cells transfected with Op-IL4

[0097] This example verifies the property of Op-IL4-transfected H9C2 cells expressing protein to induce IL-4-mediated M2 polarization in RAW 264.7 macrophages. The specific operation is as follows:

[0098] To prepare IL-4-rich conditioned medium, an optimized electroporation program (Program O6, MaxcyteExPERT ATx) was used to electroporate 20 μg of IL-4 mRNA or Op-IL4 mRNA into H9C2 cardiomyocytes (5 × 10⁻⁶ cells). 6(Number of cells). After electroporation, cells were cultured for 24 hours in complete DMEM supplemented with 10% fetal bovine serum (FBS). Control conditioned medium was prepared under the same conditions by electroporation transfection with luciferase mRNA. After 24 hours, cell culture supernatant was collected, centrifuged at 300 × g for 5 minutes at 4°C to remove cell debris, and filtered through a 0.2 μm sterile filter. RAW 264.7 macrophages were cultured in 12-well plates to 70–80% confluence and treated with IL-4-rich conditioned medium or control conditioned medium for 24 hours. After treatment, the mRNA levels of macrophage M2-related markers (including Arg1, CD206, and TGF-β1) were analyzed by quantitative real-time PCR (qPCR) to assess the polarization of M2 macrophages. Total RNA was extracted and cDNA was synthesized using standard methods. Gapdh was used as an internal reference gene, and the gene expression level was quantified using the comparative ΔΔCt method. All samples were tested in triplicate.

[0099] Figure 6 These are representative immunofluorescence images from Example 1 of this invention, showing how the expression of Op-IL4 in H9C2 cells promotes macrophage polarization. Figure 6 The image shows co-staining of the pan-macrophage marker CD68 (green) and the M2 macrophage-specific marker CD206 (red), with DAPI counterstaining the cell nuclei (blue) (scale bar 10 µm). Figure 7 This is a graph showing the relative mRNA expression levels of the M2 macrophage markers CD206, Arg-1, and TGF-β1 induced by the expression proteins of IL4 or Op-IL4 transfected cells in Example 1 of this invention (n = 3).

[0100] like Figure 6 As shown, macrophages induced by Op-IL4 were able to co-express CD68 (a universal marker) and CD206 (an M2-specific marker). Figure 7 As shown, RT-PCR analysis revealed a significant upregulation of the expression levels of CD206, Arg-1, and TGF-β1 genes in the induced group. These results confirm that IL-4 conditioned medium effectively promotes the polarization of macrophages towards the anti-inflammatory M2 phenotype, indicating that the proteins expressed in H9C2 cells transfected with Op-IL4 have sufficient activity.

[0101] 2. Anti-inflammatory effects of proteins expressed in H9C2 cells transfected with Op-IL-10

[0102] To verify the anti-inflammatory effect of proteins expressed in H9C2 cells transfected with Op-IL-10, a lipopolysaccharide-induced inflammatory injury model was first established in H9C2 cells. The establishment process is as follows:

[0103] H9C2 cells were exposed to different concentrations of lipopolysaccharide (LPS; 1, 2, and 5 μg / mL) for 24 hours. Cell viability was assessed using the CCK-8 assay. The results showed that a concentration of 2 μg / mL of LPS significantly decreased cell viability but did not induce significant cell death; therefore, this concentration was selected as the optimal stimulation condition for subsequent inflammatory injury experiments.

[0104] Using an optimized transfection protocol, H9C2 cells (5 × 10⁶) were transfected using program O6. 6 Cells were electroporated and transfected with 20 μg IL-10 mRNA / Op-IL-10 mRNA or Luciferase mRNA as a control. After recovery culture in complete DMEM containing 10% fetal bovine serum (FBS) for 24 hours, they were incubated with 2 μg / mL LPS for 24 hours to induce inflammatory damage. After LPS treatment, cell culture supernatant was collected and the secretion of pro-inflammatory cytokines was analyzed. The levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were quantified using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol. All analyses were performed in triplicate and results were normalized to protein concentration or cell number where applicable.

[0105] Figure 8 This is a graph showing the detection results of pro-inflammatory cytokine release in an inflammatory injury model of H9C2 cells transfected with Op-IL-10 according to Example 1 of the present invention. Figure 9 This is a graph showing the ELISA quantitative measurement results of the levels of cytokines (IL-1β, TNF-α and IL-6) in H9C2 cells transfected with IL-10 or Op-IL-10 in Example 1 of this invention (n = 3).

[0106] like Figure 8 As shown, ELISA analysis of cell culture supernatant revealed that the release of pro-inflammatory cytokines IL-1β, TGF-α, and IL-6 significantly increased with increasing LPS concentration. Figure 9 As shown, transfection of IL-10 and Op-IL10 mRNA into H9C2 cells effectively inhibited the expression of inflammatory factors. Among them, H9C2 cells transfected with Op-IL10 showed superior anti-inflammatory effects compared to IL-10.

[0107] 3. Effects of Op-VEGFA transfection of H9C2 cells on human umbilical vein endothelial cells

[0108] To evaluate the effects of VEGFA mRNA transfection of H9C2 cells on human umbilical vein endothelial cells (HUVECs), this example assessed the angiogenesis and migration abilities of these cells in different treatment groups. The specific procedures are as follows:

[0109] Assessment of the impact on angiogenesis capacity: Primary human umbilical vein endothelial cells (HUVECs) were trypsinized, and the cell pellet was collected by centrifugation at 300 × g for 5 min and resuspended in conditioned medium collected from transfected H9C2 cells. Cells were seeded at a density of 5 × 10³ cells per well in 48-well plates pre-coated with 100 μL / well of growth factor-depleted Matrigel (Corning, USA, 356231) and incubated at 37°C in a humidified incubator with 5% CO2 for 6–8 h to promote tubular formation. After incubation, five random and non-overlapping fields of view per well were imaged using a fluorescence microscope (Leica DMI3000 B). The formation of tubular structures was quantified using the Angiogenesis Analyzer plugin in ImageJ software, with total tube length as the primary reading.

[0110] The impact on cell migration ability was assessed using a scratch assay: HUVECs were sputtered at 5 × 10⁶ cells / well. 5 Cells were seeded at a density of 10% DMEM supplemented with 10% fetal bovine serum in 6-well plates and incubated at 37°C with 5% CO2 until 80-90% confluence. This was followed by a 12-hour serum starvation treatment (using FBS-free DMEM). A straight scratch wound was manually created in each well using a 200 μL pipette tip. The wound area was rinsed three times with PBS to remove exfoliated cells. HUVEC monolayers were then exposed to conditioned medium collected from transfected H9C2 cells. Images were captured at different time points after wound creation using an inverted microscope to monitor wound closure. Image analysis was performed using ImageJ software, and wound area was quantified as the reduction in scratch width relative to baseline (0 hours). Results are expressed as mean ± standard deviation (SD).

[0111] Figure 10 These are images showing the effects of VEGFA and Op-VEGFA-expressed proteins from H9C2 cells transfected with VEGFA in Example 1 of this invention on angiogenesis in HUVECs. Figure 11These are images showing the results of HUVECs cell migration following transfection of H9C2 cells with VEGFA and Op-VEGFA proteins from Example 1 of this invention. Figure 12 The figure shows the results of the analysis of the effects of VEGFA and Op-VEGFA transfected cell expression proteins on endothelial tube formation (branching and tube number) and wound healing ability of HUVECs in Example 1 of this invention (n = 3).

[0112] like Figures 10-12 As shown, compared with the control group, HUVECs treated with conditioned medium after transfection with VEGFA and Op-VEGFA mRNA showed significantly enhanced angiogenesis potential and migration speed, and both treatment groups showed good angiogenesis-promoting effects.

[0113] 4. Effects of Op-bFGF transfection on apoptosis in H9C2 cells under hypoxic conditions

[0114] This embodiment investigated the effect of bFGF or Op-bFGF transfection on H9C2 cell apoptosis under hypoxic conditions. The specific procedures are as follows:

[0115] H9C2 cells were cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, under a humidified environment of 37°C and 5% CO2. Cells were sputtered at 1 × 10⁶ cells per well. 5 Cells were seeded at a density of [number] cells per well in 12-well plates and allowed to adhere overnight before experimental treatment. Apoptosis was assessed using the Annexin V-FITC / PI apoptosis detection kit, following the manufacturer's instructions. Apoptotic cell populations were analyzed using a CytoFLEX flow cytometry system, and data were acquired and analyzed using CytExpert software. Live cells, early apoptotic cells, and late apoptotic / necrotic cells were distinguished based on Annexin V and PI staining results.

[0116] Figure 13 This is a flow cytometry analysis result of apoptotic cell populations after transfection with bFGF or Op-bFGF mRNA according to Example 1 of the present invention. Figure 14 Is with Figure 13 The corresponding analysis results are shown in a bar chart.

[0117] like Figure 13 , Figure 14 As shown, compared with the Luc group, bFGF or Op-bFGF mRNA transfection significantly reduced hypoxia-induced apoptosis in H9C2 cells, and there was no significant difference in anti-apoptotic effects.

[0118] 5. Expression levels of four optimized mRNAs transfected with hiPSC-CMs in rat heart tissue

[0119] Since the expression level of mRNA in the myocardial infarction region is directly related to the treatment outcome, this example also verified the expression levels of four optimized mRNAs in rat heart tissue. The specific procedures are as follows:

[0120] Four optimized mRNAs were transfected into hiPSC-CMs. The human induced pluripotent stem cells (hiPSCs) were a gift from the Chinese Academy of Sciences, obtained by reprogramming human foreskin fibroblasts. The culture and differentiation of hiPSCs into cardiomyocytes (CMs) were performed according to existing techniques. Beating hiPSC-CMs were obtained through culture and differentiation, and then purified 2-3 times to obtain hiPSC-CMs. The four optimized mRNAs were then electroporated into hiPSC-CMs to obtain hiPSC-CMs transfected with the four optimized mRNAs (i.e., graft cells used in the Cocktail therapy of this invention, hereinafter referred to as "Cocktail hiPSC-CMs").

[0121] Cocktail hiPSC-CMs were injected into the heart of rats using a 27 G needle, with a total injection volume of 150 µL per rat (total injection volume of 5 × 10⁻⁶). 6 (Each cell was injected at three sites, with a volume of 50 µL at each site). Subsequently, rats were sacrificed at different time points after surgery, and heart tissue was collected. The expression levels of four optimized mRNAs were quantitatively analyzed using ELISA.

[0122] Figure 15 This is a graph showing the ELISA quantitative analysis results of four factors in rat heart tissue at different time points after Cocktail hiPSC-CMs transplantation in Example 1 of this invention (n = 4).

[0123] like Figure 15 As shown in the ELISA analysis, the four optimized mRNA expression proteins exhibited a time-dependent expression pattern in rat heart tissue, with significantly higher expression levels at 24, 72, and 120 hours post-surgery compared to the Luc group. This time expression profile provides crucial evidence for refining the treatment regimen.

[0124] Example 2

[0125] This embodiment verifies the effect of cardiomyocytes infused with optimized IL4, IL10, VEGFA, and bFGF mRNA on functional recovery after myocardial infarction in rats. The specific process is as follows:

[0126] Male Sprague–Dawley rats (8–10 weeks old, weighing 200–250 g) were purchased from Shanghai Jihui Laboratory Animal Co., Ltd. The myocardial infarction (MI) model was established by permanent ligation of the left anterior descending artery (LAD). Specifically, rats were anesthetized with 2–3% isoflurane, mechanically ventilated, and underwent left thoracotomy. The LAD was ligated 2–3 mm distal to the left atrial appendage using 6-0 non-absorbable sutures. Criteria for successful MI induction included regional ST-segment elevation on electrocardiogram and gross pallor of the myocardium.

[0127] Immediately after successful MI induction, hiPSC-CMs cells were injected into the myocardium at three predetermined sites using a 27 G needle in the infarct border region of the rat heart. The total injection volume per rat was 150 µL (total injection volume 5 × 10⁻⁶). 6 Cells were divided into 3 sites, with an injection volume of 50 µL at each site. The culture, differentiation, and transfection process of hiPSC-CMs in each group were the same as in Example 1. The specific experimental groups are as follows:

[0128] Sham group: sham surgery group, only anesthesia and left thoracotomy were performed, but non-absorbable sutures were not used for ligation and modeling.

[0129] MI group (i.e. PBS group): After ligation with non-absorbable sutures, intramyocardial hiPSC-CMs cell injection was no longer performed, but 150 µL of PBS was injected instead.

[0130] MI-CMs luc Group: hiPSC-CMs transfected with luciferase mRNA were injected.

[0131] MI-CMs 10+4 Group: hiPSC-CMs transfected with Op-IL-10 and Op-IL-4 mRNA were injected.

[0132] MI-CMs V+b Group: hiPSC-CMs transfected with Op-VEGFA and Op-bFGF mRNA were injected.

[0133] MI-CMs Cocktail Group: Injection of Cocktail hiPSC-CMs.

[0134] In all the groups mentioned above, those injected with post-transfected hiPSC-CMs can be considered as treatment groups, including the group injected with Cocktail hiPSC-CMs (i.e., MI-CMs). Cocktail The group is the Cocktail treatment group.

[0135] Figure 16 This is an image showing the electrocardiogram monitoring results of the rat MI model constructed in Example 2 of this invention. Figure 17 This is a graph showing the measurement results of left ventricular injury in the rat MI model constructed in Example 2 of this invention. Figure 16 In the middle, the left side represents the normal control group, and the right side represents the MI group.

[0136] like Figure 16 A myocardial infarction (MI) model was successfully established in experimental rats. Characteristic ST-segment elevation was observed in all cases 5 minutes after ligation of the left anterior descending coronary artery. Figure 17 As shown, 24 hours post-surgery, TTC staining clearly revealed the boundary of MI, and quantitative analysis showed that the left ventricular injury area was consistent, approximately 38%.

[0137] Figure 18 This is a cardiac echocardiogram of a rat three days after myocardial infarction, according to Example 2 of the present invention.

[0138] like Figure 18 As shown, echocardiography three days post-surgery revealed significant left ventricular systolic dysfunction in all five experimental groups, with left ventricular ejection fraction (LVEF) decreasing to 27-38%. No statistically significant differences were observed among the groups.

[0139] To evaluate the restorative effect of op-mRNA-loaded hiPSC-CMs on left ventricular function, this embodiment performed echocardiographic assessment in a myocardial infarction (MI) model, including six groups: Sham group, MI group, and MI-CMs. Luc Group, MI-CMs 10+4 Group, MI-CMs V+b Groups and MI-CMs Cocktail Group.

[0140] Cardiac function was assessed using transthoracic echocardiography in each group. The procedure involved anesthesia of rats with 1.5% isoflurane and maintenance of a constant body temperature using a heated operating table. Ultrasound assessment was performed using a Vevo 3100 ultrasound system equipped with an MS-250 probe. Long-axis and short-axis images were acquired to measure left ventricular end-diastolic and end-systolic diameters. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were calculated based on these measurements using built-in software. Each measurement was recorded for five consecutive cardiac cycles to calculate the average. All echocardiographic analyses were performed by uninformed technicians to ensure objectivity.

[0141] Figure 19 These are representative echocardiograms of rats in each group of rats at 1, 2, and 4 weeks after myocardial infarction, as described in Example 2 of this invention. Figure 20This is a graph showing the quantitative assessment results of left ventricular function in each group of rats after myocardial infarction at 1, 2 and 4 weeks after the infarction in Example 2 of the present invention, expressed as ejection fraction (LVEF) and left ventricular fraction shortening rate (LVFS) (n = 8).

[0142] like Figure 19 , Figure 20 As shown, in the first week after surgery, only MI-CMs Cocktail The treatment group showed significant improvements in LVEF and LVFS compared to the MI group. By week two, all treatment groups showed significantly better LVEF and LVFS than the MI group, with MI-CMs showing even greater improvement. 10+4 MI-CMs V +b and MI-CMs Cocktail The treatment efficacy of the group was superior to that of MI-CMs Luc Group. It is worth noting that MI-CMs Cocktail The group showed the best treatment outcome. In the final evaluation 4 weeks post-surgery, MI-CMs... Cocktail The treatment group achieved the best results (LVEF 52.79% ± 4.51%, LVFS 26.21% ± 1.05%), significantly better than other treatment groups. MI-CMs V+b Group (LVEF 43.54% ± 1.90%, LVFS 22.08% ± 1.73%) and MI-CMs 10+4 The treatment groups (LVEF 43.15% ± 2.20%, LVFS 22.18% ± 1.55%) also showed significant therapeutic effects. Importantly, all treatment groups performed significantly better than the non-treatment control group. Therefore, cocktail treatment using hiPSC-CMs loaded with the four Op-mRNAs of this invention can effectively enhance cardiac function after myocardial infarction.

[0143] Furthermore, this embodiment used mapping technology to evaluate the electrical conduction characteristics of the left ventricle in each group. Specifically, an 8 × 8 multi-electrode array (MEA) was placed on the epicardial surface of the exposed heart to collect electrical signals. The signals were amplified, filtered, and digitized by a filter amplifier before being transmitted to a computer in real time for data acquisition and analysis. Activation time was defined as the point with the steepest negative slope of the recorded action potential. These data were used to generate epicardial activation maps.

[0144] Figure 21 This is a representative 64-channel left ventricular activation map (thermograph) of each group of rats 4 weeks after myocardial infarction in Example 2 of the present invention, showing the electrical activity patterns and conduction velocities. Figure 22 This is a graph showing the quantitative analysis results of ventricular conduction parameters (time, velocity, and heterogeneity) of each group of rats 1 week and 4 weeks after myocardial infarction in Example 2 of the present invention (n = 8).

[0145] like Figure 21 , Figure 22 As shown, compared with the Sham group, the other experimental groups all exhibited varying degrees of conduction abnormalities. However, the MI group showed a significant increase in signal disturbances one week post-surgery, while all four treatment groups showed an improving trend in parameters such as conduction time (CT), conduction velocity (CV), and dispersion. By the fourth week, all treatment groups, especially MI-CMs, showed improvement. Cocktail The treatment group exhibited a more regular conduction pattern and reduced dispersion. Specifically, MI led to prolonged CT, decreased CV, and exacerbated signal disturbances, but these abnormalities were significantly reversed in all treatment groups, particularly in MI-CMs. Cocktail The group showed the most significant improvement.

[0146] To systematically evaluate the improvement of heart tissue in rats with myocardial infarction (MI) after transplantation, this example further compared and analyzed heart specimens from the above groups at 1 week and 4 weeks post-surgery. Specifically, rats were sacrificed at designated time points, and their hearts were removed and immediately fixed in 10% neutral buffered formalin solution. After graded dehydration with ethanol, the tissues were embedded in paraffin and cut into 5 μm thick serial sections. After spreading and mounting, the sections were analyzed as follows: hematoxylin-eosin (H&E) staining and Masson's trichrome staining were used to assess infarct area, scar tissue percentage, and left ventricular wall thickness.

[0147] Figure 23 These are representative H&E-stained cardiac tissue slices from each group of rats 4 weeks after myocardial infarction in Example 2 of this invention (overview scale bar, 2 mm; magnified view scale bar, 500 µm). Figure 24 This is a quantitative analysis result of the left ventricular wall thickness of H&E sections from each group of rats at 1 week and 4 weeks after myocardial infarction in Example 2 of the present invention (n = 8).

[0148] like Figure 23 , Figure 24 As shown, MI-CMs Cocktail The left ventricular wall thickness of the group was significantly increased, showing the most significant enhancement effect, indicating that the Cocktail therapy of the present invention can not only promote myocardial repair, but also effectively prevent ventricular wall thinning and ventricular dilation, thereby significantly slowing the pathological progression of heart failure.

[0149] Example 3

[0150] This embodiment verifies the effect of the optimized composition of IL4, IL10, VEGFA, and bFGF mRNA on the viability of myocardial grafts (i.e., hiPSC-CMs). In this embodiment, the experimental groups are the same as in Example 2, and the cardiomyocytes in each group are taken from the corresponding rat hearts in Example 2.

[0151] Existing research indicates that hiPSC-CMs primarily exert their therapeutic effects through paracrine mechanisms. This embodiment specifically evaluated the in vivo survival characteristics of cocktail hiPSC-CMs. The procedure involved: HE staining was used to determine the tissue morphology of rat myocardial tissue from each group in Example 2; green fluorescent protein (GFP) labeling was used to track cocktail hiPSC-CMs; and cTnT and GFP dual immunofluorescence staining was used for detection.

[0152] Figure 25 This refers to hMI-CMs 4 weeks post-transplantation in Example 3 of this invention. Cocktail HE staining images of viable myocardial grafts in the ischemic zone (IZ) and marginal zone (BZ). Figure 26 , Figure 27 These are representative immunofluorescence images of the infarct margin region at 1 week and 4 weeks after myocardial infarction in Example 3 of the present invention, showing co-localization of graft-derived cardiomyocytes (cTnT, red) and GFP-labeled transplanted cells (green).

[0153] As shown in Figures 25-27, GFP-positive hiPSC-CMs were detected in myocardial tissue in all groups at 1 and 4 weeks post-treatment. These transplanted cells were mainly located in and around the infarcted area, indicating significant local retention.

[0154] Figure 28 This is a graph showing the quantitative analysis results of relative GFP fluorescence intensity in cardiac tissue at 1 week and 4 weeks after myocardial infarction in Example 3 of the present invention (n = 8).

[0155] like Figure 28 As shown, hiPSC-CMs loaded with Op-mRNA exhibited significantly enhanced survival rates in the infarct region, with MI-CMs loaded with four different Op-mRNAs showing particularly strong performance. Cocktail The group showed the most significant effect.

[0156] Figure 29 These are confocal microscopy images of TUNEL (red) and cTnT (green) positive cardiomyocytes in the marginal zone (BZ) at 1 and 4 weeks after myocardial infarction in Example 3 of this invention, with cell nuclei counterstained with DAPI (scale bar, 50 µm). Figure 30This is a graph showing the quantitative analysis results of TUNEL-positive cardiomyocytes per field of view in six groups of the present invention at 1 week and 4 weeks after myocardial infarction.

[0157] like Figure 29 As shown, MI-CMs V+b Groups and MI-CMs Cocktail The group showed a significant cardioprotective effect. For example... Figure 30 As shown, although MI-CMs Luc and MI-CMs 10+4 The treatment group showed a slight trend toward reduced cell death in the early stages, but the difference was not statistically significant; in contrast, the first two regimens maintained a clear therapeutic advantage even 4 weeks post-surgery. Further validation using the cardiac marker cTnT confirmed that these treatment regimens specifically reduced cardiomyocyte death, particularly at 4 weeks post-treatment, where their protective effect was more pronounced.

[0158] Example 4

[0159] This embodiment verifies the effects of the optimized composition of IL4, IL10, VEGFA, and bFGF mRNA on angiogenesis and myocardial fibrosis in myocardial grafts. In this embodiment, the experimental groups were the same as in Example 2, and the cardiomyocytes in each group were taken from the corresponding rat hearts in Example 2. Furthermore, in this embodiment, analytical methods and procedures not specified were performed according to Example 2, or according to existing analytical methods and procedures.

[0160] 1. Staining analysis of cells with pro-angiogenic effects

[0161] For transplanted cardiomyocytes, adequate blood supply is crucial for their long-term survival. To verify whether cocktail therapy truly has an angiogenic effect, this study used CD31 and α-SMA staining to assess angiogenesis in each experimental group.

[0162] Figure 31 These are confocal micrographs of CD31 and α-SMA stained in Example 4 of the present invention, showing the co-expression of α-SMA and CD31 in the infarct zone (IZ) and the marginal zone (BZ). Figure 32 yes Figure 31 The corresponding quantitative analysis results are shown in the figure.

[0163] like Figure 31 As shown, compared to other experimental groups, after 4 weeks, MI-CMs V+b and MI-CMs CocktailIn the treatment group, the cardiac tissue not only formed a dense capillary network but also structurally intact arterioles, resulting in a significantly better therapeutic effect than other treatment options. Figure 40 As shown, quantitative analysis revealed that the vascular density in the treatment group was three times that of the control group.

[0164] Combination Figure 31 , Figure 32 It can be seen that neovascularization exhibits typical "onion skin"-like thickening of the vessel wall and co-expresses bimolecular markers, confirming its full functional characteristics as a mature vessel. Furthermore, such as Figure 31 As shown, significant neovascularization was also observed in the marginal region of MI.

[0165] 2. Analysis of cardiomyocyte fibrosis

[0166] To further elucidate the potential mechanisms of improved cardiac function, this embodiment provides a comprehensive assessment of myocardial fibrosis.

[0167] Figure 33 This is a Masson trichrome staining image of rat heart tissue after myocardial infarction, as described in Example 4 of this invention.

[0168] like Figure 33 As shown, Masson staining and quantitative analysis revealed that MI-CMs Cocktail In the rats of the group, the area of ​​left ventricular scars was significantly reduced at 1 and 4 weeks after MI, and the thickness of the ventricular wall was well maintained.

[0169] Figures 34-36 The results are the staining detection results of the inflammatory markers CD3, CD68, and MIPO one week after the operation of Example 4 of the present invention. Figures 34-36 In the diagram, 'a' represents the stained images of the corresponding inflammatory markers, and 'b' represents the bar charts of the results corresponding to 'a'.

[0170] like Figures 34-36 As shown, the staining results of inflammatory markers one week after surgery indicate that the Cocktail therapy of the present invention can effectively regulate the inflammatory response.

[0171] Figure 37 This is a representative immunofluorescence image of cardiomyocytes from Example 4 of the present invention, showing the colocalization of cTnT (green) and type I collagen (red), and cTnT (green) and type III collagen (red) in the infarct zone (IZ) 4 weeks after MI, and counterstained with DAPI (scale bar, 50 µm). Figure 38 This is a graph showing the quantitative analysis results of the content of type I and type III collagen in each group of heart tissue in Example 4 of the present invention (n = 8).

[0172] like Figure 37 , Figure 38 As shown, at 4 weeks, collagen staining revealed that all cell therapy groups effectively inhibited abnormal accumulation of collagen fibers in the marginal zone, with MI-CMs showing the highest levels of inhibition. 10+4 and MI-CMs Cocktail The combined treatment group showed particularly significant results.

[0173] Figure 39 This is the result of vimentin staining in cardiomyocytes 4 weeks after myocardial infarction, according to Example 4 of the present invention. Figure 39 In the diagram, 'a' represents the stained image, and 'b' is the corresponding histogram of the result.

[0174] like Figure 39 As shown, vimentin staining further revealed that although the infarcted area still exhibited significant fibroblast infiltration after MI, all treatment groups showed a significant reduction in fibroblast aggregation, especially in MI-CMs. 10+4 and MI-CMs Cocktail Group.

[0175] Based on the above experimental results, the Cocktail therapy of the present invention enhances cardiac function through three protective mechanisms: effectively inhibiting myocardial fibrosis, improving ventricular pathological remodeling, and delaying the progression of myocardial damage.

[0176] Example 5

[0177] This embodiment validates the role of heart grafts loaded with Cocktail mRNA in a porcine myocardial infarction model.

[0178] This embodiment successfully established a model highly simulating human acute myocardial infarction (MI) by ligating the left anterior descending coronary artery (LAD) of pigs. The procedure was as follows: female Large White pigs (6–7 months old, weighing 45–50 kg; purchased from Shanghai Yinshe Medical Technology Co., Ltd., China) were selected. In accordance with standard surgical guidelines, the mid-segment of the LAD was ligated and occluded through open-chest surgery to construct a large-area anterior septal myocardial infarction (MI) model.

[0179] After 90 minutes of modeling, 1×10 8 Cocktail hiPSC-CMs were injected into the infarct area and marginal zone. The experimental group is as follows:

[0180] MI-PBS group: After ligation during open-chest surgery, 3 mL of PBS was injected.

[0181] MI-CMs Cocktail Group: Injected with 1×10 8 Cocktail hiPSC-CMs (3 mL each).

[0182] Figure 40 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Representative lead II ECG trajectories recorded at different time points in the group. Figure 41 These are representative lead II electrocardiogram trajectories recorded at different time points in the MI group of Embodiment 5 of the present invention.

[0183] like Figure 40 , 41 As shown, the ECG on day 0 (intraoperative real-time) displayed typical features of acute MI: ST-segment elevation resembling a "red flag" pattern accompanied by significant T waves. By day 3, "tombstone-like" ST-segment elevation with T-wave inversion appeared, accurately replicating the pathological progression of clinical acute MI. Compared with the PBS group, MI-CMs Cocktail The electrocardiograms of the treatment group returned to normal by day 28.

[0184] Figure 42 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Echocardiographic images of left ventricular function at specific time points after myocardial infarction in the PBS group and the PT group. Figure 43 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Statistical analysis results of key left ventricular function parameters in the PBS group and the PBS group.

[0185] like Figure 43 As shown, echocardiographic results indicated that after two weeks of Cocktail treatment, various indicators of the pig's heart significantly improved. Combined with... Figure 43 It can be seen that MI-CMs Cocktail The left ventricular ejection fraction in the group increased significantly from day 14, reaching a maximum recovery of 61%, and MI-CMs Cocktail The data differences between the group and the PBS group were statistically significant.

[0186] Figure 44 This is the MI-CMs of Embodiment 5 of the present invention. Cocktail Representative short-axis MRI images of the heart morphology (basal segment, mid-ventricular segment, and apical segment, with the infarct area marked in color) of the group and the PBS group before myocardial infarction surgery, 3 days after surgery, and 28 days after surgery. Figure 45 Is with Figure 44 The corresponding quantitative analysis results of functional parameters based on MRI assessment are shown in the figure. Figure 46 This is a polar coordinate diagram (bull's eye diagram) representing the regional myocardial function at three ventricular levels at different time points in Embodiment 5 of the present invention. Figure 47 Is with Figure 46The corresponding quantitative analysis results of the functional parameters based on the bullseye chart assessment are shown in the figure.

[0187] like Figures 44-47 As shown, a systematic evaluation using MRI revealed that, compared to the PBS control group, MI-CMs Cocktail The group exhibited the following characteristics: 1) thickening of the myocardial layer and enhanced contractile function; 2) continuous reduction of MI area; 3) significant reduction in scar formation; 4) significant increase in ventricular wall thickness.

[0188] Figure 48 shows the MI-CMs of Embodiment 5 of the present invention. Cocktail Coronary angiography images acquired 28 days after myocardial infarction in the control group and the PBS group.

[0189] like Figure 48 As shown, the angiography images reveal a dense network of new blood vessels forming in the treated area of ​​myocardial infarction.

[0190] Based on the above results, the Cocktail treatment of the present invention promotes cardiac repair through the following three mechanisms: effectively reducing necrotic tissue, promoting myocardial structural reconstruction, and significantly enhancing cardiac pumping function.

[0191] Example 6

[0192] This embodiment verifies the role of cocktail mRNA-loaded myocardial grafts in angiogenesis, apoptosis, and pathological remodeling after myocardial infarction in pigs. In this embodiment, the experimental groups are the same as in Example 5, and the cardiomyocytes in each group are taken from the corresponding pig hearts in Example 5. Furthermore, unless otherwise specified, in this embodiment, MI-CMs... Cocktail The n=5 group and the n=3 group of MI-PBS.

[0193] Figure 49 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Images of heart specimens collected on day 28 in the control group and the PBS group, each specimen was divided into six transverse sections from the apex to the base (scale bar, 2 cm).

[0194] like Figure 49 As shown, macroscopic observation revealed that the myocardial infarction area in the heart of the pig treated with Cocktail perfectly matched the MRI image in Example 5.

[0195] Figure 50 This is the MI-CMs of Embodiment 6 of the present invention. CocktailRepresentative H&E and Masson stained tissue sections from the MI-PBS group at 4 weeks post-myocardial infarction, showing an overview and magnified view (scale bars 5 mm and 100 µm, respectively). Figure 51 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the results of quantitative analysis of infarct area and left ventricular wall thickness 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0196] like Figure 50 , Figure 51 As shown, histopathological examination revealed a significant reduction in scar area in the experimental group, with a dense network of new blood vessels visible under a microscope.

[0197] Figure 52 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence co-staining images of CD31⁺ capillaries (red) and α-SMA⁺ adventitia cells (green) in the infarct zone (IZ) and boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the infarct group (magnified area scale bar, 50 µm). Figure 53 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail The vascular morphology analysis results of the infarct group and the MI-PBS group include capillary density (CD31⁺), mature vessel density (CD31⁺ / α-SMA⁺), and layered mature vessel structure in the infarct zone (IZ) and boundary zone (BZ). Figure 54 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Representative TUNEL staining (green) and DAPI counterstaining images of apoptotic cells in the boundary zone (BZ) of myocardial infarction 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group (scale bar, 50 µm). Figure 55 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the quantitative analysis results of TUNEL-positive cell nuclei in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0198] like Figure 52 , Figure 54 As shown, the treatment of this invention not only promotes capillary proliferation but also establishes a functional microartery system. For example... Figure 54 , Figure 55 As shown, the treatment of the present invention also significantly reduces the apoptosis rate of cardiomyocytes.

[0199] Figure 56 This is the MI-CMs of Embodiment 6 of the present invention. CocktailImmunofluorescence staining of vimentin (green) in the boundary zone (BZ) of myocardial infarction in the MI-PBS group and the MI-PBS group 4 weeks after myocardial infarction, with DAPI counterstaining images (scale bar, 50 µm). Figure 57 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Figure showing the quantitative analysis results of vimentin-positive cells in the heart tissue of the MI-PBS group and the MI-PBS group.

[0200] like Figure 56 , Figure 57 As shown, although fibroblasts were present in both experimental groups, the number of fibroblasts in the MI-CMs group was significantly higher than that in the MI-PBS group. Cocktail The group effectively inhibited their pathological accumulation.

[0201] Figure 58 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence colocalization images of cTnT (green) and type I collagen (red) in the boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group (scale bar, 50 µm). Figure 59 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Quantitative analysis results of type I collagen-positive areas in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group. Figure 60 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Immunofluorescence colocalization images of cTnT (green) and type III collagen (red) in the boundary zone (BZ) 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group (scale bar, 50 µm). Figure 61 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail Quantitative analysis results of type III collagen-positive areas in cardiac tissue 4 weeks after myocardial infarction in the MI-PBS group and the MI-PBS group.

[0202] like Figures 58-61 As shown, further analysis indicates that the therapy of the present invention significantly prevents the accumulation of harmful collagen fibers.

[0203] Figure 62 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail The image shows the results of quantitative PCR analysis of Y chromosome DNA in the infarct zone (IZ) 4 weeks after myocardial infarction in the MI-PBS group and the infarct group, indicating the implantation of male donor-derived cells.

[0204] like Figure 62 As shown, Y chromosome tracking technology was used in MI-CMs Cocktail Surviving transplanted cardiomyocytes were detected in the heart tissue of the group.

[0205] The above findings collectively demonstrate that the Cocktail therapy of the present invention creates a microenvironment for the long-term survival of transplanted cells through three mechanisms: cardiomyocyte protection, enhanced angiogenesis, and inhibition of fibrosis, thereby achieving multidimensional cardiac function reconstruction.

[0206] This embodiment further evaluated the safety of Cocktail mRNA-transfected engineered cells in pigs. All experimental animals survived during the 28-day observation period and showed no significant clinical abnormalities. Furthermore, 72-hour continuous electrocardiogram monitoring starting on day 20 post-surgery showed no fatal arrhythmias in the treatment group.

[0207] Figure 63 This is the MI-CMs of Embodiment 6 of the present invention. Cocktail The results of multiple blood biochemical indicators at multiple time points after myocardial infarction in the group and the MI-PBS group were as follows: a) troponin, b) white blood cell count, c) basophils (BAS), d) red blood cells (RBC), and e) liver and kidney function alanine aminotransferase (ALT).

[0208] like Figure 63 As shown, blood test results indicate that MI-CMs Cocktail During the treatment period, key physiological parameters such as liver and kidney function remained within the normal range.

[0209] Further systemic histopathological analysis showed that MI-CMs Cocktail No abnormal pathological changes were found in any of the vital organs in the group, including the liver, lungs, spleen, kidneys, brain, and lymph nodes.

[0210] The above analysis results demonstrate that using human induced pluripotent stem cell-derived cardiomyocytes as a biological carrier for Cocktail mRNA therapy composed of four optimized mRNAs exhibits excellent safety and tolerability in clinically relevant large animal models, providing a safety basis for clinical translation.

Claims

1. An mRNA composition for treating or improving acute myocardial infarction, characterized in that, include: The optimized IL4 mRNA sequence is shown in SEQ ID No. 1; The optimized IL10 mRNA sequence is shown in SEQ ID No. 2; The optimized VEGFA mRNA sequence is shown in SEQ ID No. 3; The optimized bFGF mRNA sequence is shown in SEQ ID No.

4.

2. An engineered cell for treating or improving acute myocardial infarction, characterized in that, Obtained by transfecting cardiomyocytes with the mRNA composition as described in claim 1.

3. The engineered cells for treating or improving acute myocardial infarction according to claim 2, characterized in that: in, The cardiomyocytes are human induced pluripotent stem cell-derived cardiomyocytes.

4. A graft for treating or improving acute myocardial infarction, characterized in that, It contains engineered cells as described in claim 2 or 3.

5. The graft for treating or improving acute myocardial infarction according to claim 4, characterized in that, It also contains fat-derived stem cells.

6. The graft for treating or improving acute myocardial infarction according to claim 4, characterized in that, The graft is a cardiac spheroid or a self-organizing 3D organoid.